Employees at Pfizer Inc’s U.S. research centers may want to dust off their resumes if the company’s proposed acquisition of Britain’s AstraZeneca comes to fruition.
Employees at Pfizer Inc’s U.S. research centers may want to dust off their resumes if the company’s proposed acquisition of Britain’s AstraZeneca comes to fruition.